Daxor (DXR) Stock Price

Daxor Price

NYSE AMEX·CLOSED
10.51
​
Market closed

Revenue at Daxor has contracted by 5.5% per year over the past 19 years to 503,424.00 USD. Earnings per share have declined at 1.6% per year over the last 18 years. For Daxor, the net margin of 1,821.5% is up versus 81.6% a few years ago. At today's price the dividend yield works out to roughly 0.29%. The consensus 12-month price target for Daxor is 23.46 USD, about 123.2% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

Daxor stock price

Access this data via the Eulerpool API

Daxor business model & stock analysis

Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. The company is headquartered in New York City, New York. The firm has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. The company is also focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. The company has several ongoing trials in the areas of heart failure treatment with support from the National Institutes of Health (NIH) and is under contract developing analyzers.

Frequently asked questions about Daxor

Analysts currently set an average price target of 23.80 USD for the Daxor stock (median: 23.46 USD), implying +126.5 % versus the latest price. The consensus is based on 5 analyst ratings.

6 analysts currently rate the Daxor stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Daxor to generate revenue of 9.30 M USD and earnings per share of -0.21 USD.

Converted at the current exchange rate, the Daxor share trades at 9.38 EUR (10.51 USD).

The Daxor share (DXR) is listed on 3 stock exchanges, including: NASDAQ (DXR), Frankfurt (DX5.F).

The expected revenue of Daxor is 9.30 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Daxor is -1.06 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Daxor is currently -50.05. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Daxor stock.

The price-to-sales ratio (P/S) of Daxor is currently 5.72. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Daxor stock.

The Eulerpool Quality Score for Daxor is 4/10.

The ISIN of Daxor is US2394671034. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Daxor is 871275. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Daxor is DXR. The ticker symbol is used to trade Daxor shares on the stock exchange.

Fair ValueTerminal
9.98 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website daxor.com
Currency
USD
Initial public offering
Jul 25, 1983
ISIN
US2394671034
Cusip
239467103
Market capitalization
53.18 M USDMicro Cap
52-Week Range
PEG
-0.27
P/E ratio
P/Ee 2026
-50.05
P/Ee 2027
-350.33
P/Ee 2028
26.28
P/Ee 2029
10.51
P/Ee 2030
5.84
P/Se
5.72
EV/EBIT
5.80
P/B Ratio
1.16
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
19.93 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
0.29 %
Payout Ratio
41.21 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
30.00 %
Last updated Oct 8, 2026, 6:19 PM

Daxor Peer Group

Daxor Ticker

AMEX · DXRFRANKFURT · DX5.FNASDAQ · DXR

Daxor FIGI

DXR:US · BBG000BHHF34DXR:UA · BBG000BHHF98DXR:UC · BBG000BHHFZ9DXR:UN · BBG000BHHHG6DXR:UP · BBG000BHHHP6DXR:UB · BBG000BHHJH1DXR:UM · BBG000BHHLZ6DXR:UX · BBG000BHHMY5DXR:UR · BBG000BHHN73DXR:UD · BBG000BHHQQ5DXR:UF · BBG000BHHRN6DXR:VY · BBG000BHHRV7

All fundamentals and in-depth analysis of Daxor

Our stock analysis for Daxor stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Daxor. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.